1. Scrip
  3. >>Clinical Trials

New Player Joins Search For Effective Huntington's Therapies

LoQus23 Looks To Tackle Neurodegenerative Disease

 
• By Kevin Grogan

Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.

Confused undecided businessman watches the complicated road
Huntington's drug development difficult to navigate • Source: Archive

Hopes of a breakthrough in Huntington’s disease have been dashed a number of times, not least this year, but the emergence from stealth mode of a UK biotech backed by Novartis AG's venture arm could provide some optimism down the line for patients with the fatal, inherited neurodegenerative disorder.

LoQus23 Therapeutics has closed a £7m ($9.3m) extended seed round this week after securing financing from the Novartis Venture Fund and its founding investor, the UK's Dementia Discovery Fund (DDF). This round follows an initial £4

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D